Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1171026
Max Phase: Preclinical
Molecular Formula: C23H18BF2IN2S
Molecular Weight: 530.19
Molecule Type: Small molecule
Associated Items:
ID: ALA1171026
Max Phase: Preclinical
Molecular Formula: C23H18BF2IN2S
Molecular Weight: 530.19
Molecule Type: Small molecule
Associated Items:
Synonyms (1): [125I]BODIPY7
Synonyms from Alternative Forms(1):
Canonical SMILES: CC1=CC(C)=[N+]2C1=Cc1ccc(/C=C/c3ccc(-c4ccc([125I])cc4)s3)n1[B-]2(F)F
Standard InChI: InChI=1S/C23H18BF2IN2S/c1-15-13-16(2)28-22(15)14-20-8-7-19(29(20)24(28,25)26)9-10-21-11-12-23(30-21)17-3-5-18(27)6-4-17/h3-14H,1-2H3/b10-9+/i27-2
Standard InChI Key: QMTBMZPGJSRNCT-RAMXQMIISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 530.19 | Molecular Weight (Monoisotopic): 530.0297 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ono M, Ishikawa M, Kimura H, Hayashi S, Matsumura K, Watanabe H, Shimizu Y, Cheng Y, Cui M, Kawashima H, Saji H.. (2010) Development of dual functional SPECT/fluorescent probes for imaging cerebral beta-amyloid plaques., 20 (13): [PMID:20627723] [10.1016/j.bmcl.2010.05.027] |
2. Rai H, Gupta S, Kumar S, Yang J, Singh SK, Ran C, Modi G.. (2022) Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease., 65 (13.0): [PMID:35759679] [10.1021/acs.jmedchem.1c01619] |
Source(1):